Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Clinical samples were tested for EGFR mutations by peptide nucleic acid-locked nucleic acid PCR clamp, and patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutani, A, Nagai, Y, Udagawa, K, Uchida, Y, Koyama, N, Murayama, Y, Tanaka, T, Miyazawa, H, Nagata, M, Kanazawa, M, Hagiwara, K, Kobayashi, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360739/
https://www.ncbi.nlm.nih.gov/pubmed/17106442
http://dx.doi.org/10.1038/sj.bjc.6603466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360739/
https://www.ncbi.nlm.nih.gov/pubmed/17106442
http://dx.doi.org/10.1038/sj.bjc.6603466

Ejemplares similares